Kandolf Sekulovic, L., Peris, K., Hauschild, A., Stratigos, A., Grob, J., Nathan, P., Dummer, R., Forsea, A., Hoeller, C., Gogas, H., Demidov, L., Lebbe, C., Blank, C., Olah, J., Bastholt, L., Herceg, D., Neyns, B., Vieira, R., Hansson, J., Rutkowski, P., Krajsova, I., Bylaite-Bucinskiene, M., Zalaudek, I., Maric-Brozic, J., Babovic, N., Banjin, M., Putnik, K., Weinlich, G., Todorovic, V., Kirov, K., Ocvirk, J., Zhukavets, A., Kukushkina, M., De La Cruz Merino, L., Ymeri, A., Risteski, M., & Garbe, C. (2017). more than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments. European journal of cancer, 75, 313–322. http://access.bl.uk/ark:/81055/vdc_100045081929.0x000007